Jiangsu Vcare Closes Hundreds-of-Millions-of-RMB Financing Round
Published Time:
2021-03-08 18:01
Source:
Jiangsu Vcare Pharmatech Co., Ltd. (Jiangsu Vcare) has secured financing worth hundreds of millions of CNY in a round led by SDIC Capital, with participation from Fengling Capital. The funds will accelerate Vcare’s CDMO expansion and Phase III clinical research for its innovative drug Vicagrel.
Founded in 2010, Jiangsu Vcare specializes in end-to-end R&D, services, and innovation across the chemical drug industry chain. Headquartered in Nanjing Biotech and Pharmaceutical Valley, the company employs 280 staff, with over 50% of its R&D team holding master’s or doctoral degrees. It operates a 21,000 sqm high-end drug R&D center equipped with fully functional synthesis, analysis, formulation, cell, and enzyme activity testing laboratories. Its experienced teams in medicinal chemistry, CMC, and clinical development operate under internationally advanced management models, providing comprehensive R&D capabilities spanning "Chemistry + Pharmacy + Medicine".
Focusing on unmet clinical needs in cardiovascular, oncology, and endocrine diseases, Jiangsu Vcare has developed multiple competitive innovative products through independent R&D and collaborative innovation. Its flagship drug Vicagrel—which has completed Phase II trials—was recognized as "one of the most commercially promising projects in its field." The second-generation NTRK inhibitor has entered Phase I, while a highly selective JAK1 inhibitor is nearing IND submission. The pipeline includes multiple first-in-class (FIC) and best-in-class (BIC) preclinical candidates.
In recent years, Jiangsu Vcare has steadily advanced its innovative drug programs while achieving rapid growth in contract services. With investor support, the company aims to accelerate clinical research and deliver more high-quality therapeutics to global patients.
Dr. Gong Yanchun, Co-founder and CEO of Jiangsu Vcare, stated: "We sincerely appreciate our investors’ recognition of Jiangsu Vcare and their trust in our team. We are in an exhilarating era of innovation, where developing novel drugs to address clinical needs remains our unwavering mission. Simultaneously, in this service-driven economy, we are committed to providing one-stop, full-process drug R&D services that create value for clients. Moving forward, we will continue to prioritize independent innovation and open collaboration to unlock limitless potential."
Next Page
Next Page
Related News
11
2025
/
08
August 8, 2025 – Jiangsu Vcare Pharmatech Co., Ltd. (Jiangsu Vcare) announced today that it has entered into an exclusive strategic partnership with Huadong Medicine (Hangzhou) Co., Ltd., a wholly-owned subsidiary of Huadong Medicine Co., Ltd. (000963.SZ, "Huadong Medicine"), for the commercialization rights of Jiangsu Vcare’s innovative product VC005 tablets in mainland China.
View Details
31
2025
/
07
Recently, Jiangsu Vcare Pharmatech Co., Ltd. (Jiangsu Vcare) announced the completion of full patient enrollment for its Phase II clinical trial of the self-developed, next-generation highly selective JAK1 inhibitor, VC005 topical gel, for the treatment of mild-to-moderate Atopic Dermatitis (AD). This marks a significant milestone in the VC005 gel development program.
View Details
03
2025
/
07
Recently, the NDA for Eratrectinib (VC004) capsules, a next-generation anti-resistance TRK inhibitor independently developed by Jiangsu Vcare PharmaTech Co., Ltd. (Jiangsu Vcare) has been officially accepted by China's NMPA. Previously granted priority review designation, the drug holds promise as a new treatment option for patients with advanced solid tumors.
View Details
30
2025
/
05
Recently, Eratrectinib (VC004) capsules, a self-developed next-generation anti-resistant TRK inhibitor by Jiangsu Vcare PharmaTech Co., Ltd. (Jiangsu Vcare), were included in the priority review list by the NMPA, through public notice. This milestone positions the drug within the first tier of next-generation anti-resistant products targeting the same mechanism in China.
View Details
21
2025
/
05
Recently, Jiangsu Vcare PharmaTech Co., Ltd. (Jiangsu Vcare) announced the completion of patient enrollment for its self-developed Class 1 innovative antiplatelet drug, Vicagrel Capsules, in a Phase III clinical trial conducted in China. This study evaluates the efficacy and safety of Vicagrel compared to Clopidogrel in patients with acute coronary syndrome (ACS). The milestone marks a critical step toward Vicagrel’s potential market approval.
View Details
09
2025
/
05
On May 8, 2025, Jiangsu Vcare Pharmatech Co., Ltd. (Jiangsu Vcare) achieved another major milestone in its self-developed second-generation highly selective JAK1 inhibitor, VC005 tablets. The project, intended for the oral treatment of non-segmental vitiligo received official IND approval from the NMPA (Application No.: CXHL2500200).
View Details
Company Address:
No. 136, Huakang Road, Jiangbei New Area, Nanjing, P. R. China
Subsidiary NJVcare Website：
Scan to see
Copyright © JIANGSU VCARE PHARMATECH CO.,LTD.
Powerby：www.300.cn nanjing.300.cn